Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse/Refractory Multiple Myeloma”

1,429 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,429 results

Testing effectiveness (Phase 2)Study completedNCT00040846
What this trial is testing

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+97 more
Fred Hutchinson Cancer Center 60
Large-scale testing (Phase 3)UnknownNCT00003603
What this trial is testing

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Riverside Haematology Group 660
Early research (Phase 1)Looking for participantsNCT07239323
What this trial is testing

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Who this might be right for
B-Acute Lymphoblastic LeukemiaB Cell Non-Hodgkin's LymphomaMultiple Myeloma
Chongqing Precision Biotech Co., Ltd 24
Early research (Phase 1)Ended earlyNCT03486067
What this trial is testing

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 183
Testing effectiveness (Phase 2)Study completedNCT01720875
What this trial is testing

Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

Who this might be right for
Multiple Myeloma
University of Leeds 16
Testing effectiveness (Phase 2)Ended earlyNCT02294357
What this trial is testing

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Who this might be right for
Multiple Myeloma
Oncotherapeutics 45
Early research (Phase 1)UnknownNCT04984434
What this trial is testing

Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD 68
Early research (Phase 1)Study completedNCT03111992
What this trial is testing

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals 26
Testing effectiveness (Phase 2)Looking for participantsNCT06627751
What this trial is testing

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Who this might be right for
Extramedullary Disease in Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Roswell Park Cancer Institute 28
Post-approval studies (Phase 4)Study completedNCT05555329
What this trial is testing

Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study

Who this might be right for
Multiple Myeloma in RelapseMultiple MyelomaMultiple Myeloma, Refractory
Amsterdam UMC, location VUmc 12
Early research (Phase 1)Study completedNCT03263637
What this trial is testing

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Who this might be right for
Relapsed or Refractory Haematological Malignancies IncludingAcute Myeloid LeukemiaAcute Lymphocytic Leukemia+8 more
AstraZeneca 44
Testing effectiveness (Phase 2)Study completedNCT00064311
What this trial is testing

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
National Institutes of Health Clinical Center (CC)
Not applicableStudy completedNCT00408681
What this trial is testing

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+111 more
Fred Hutchinson Cancer Center 20
Early research (Phase 1)Study completedNCT05270928
What this trial is testing

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#

Who this might be right for
Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Soochow University 6
Large-scale testing (Phase 3)Study completedNCT00452569
What this trial is testing

Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 499
Testing effectiveness (Phase 2)Ended earlyNCT03910439
What this trial is testing

Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma

Who this might be right for
Myeloma, MultipleMyeloma-Multiple
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)Looking for participantsNCT06911710
What this trial is testing

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

Who this might be right for
Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)AML (Acute Myelogenous Leukemia)Myeloma Multiple+3 more
Tianjin Medical University General Hospital 90
Very early researchNot Yet RecruitingNCT04670055
What this trial is testing

Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Who this might be right for
Relapse Multiple MyelomaRefractory Multiple Myeloma
Zhejiang University 50
Testing effectiveness (Phase 2)Study completedNCT00216697
What this trial is testing

An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

Who this might be right for
Multiple Myeloma
Janssen Pharmaceutical K.K. 13
Testing effectiveness (Phase 2)Ended earlyNCT01997840
What this trial is testing

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 103
Next Page